Accessibility to Rituximab and its impact on treatment outcomes in major Non-Hodgkin Lymphoma subtypes: Insights from a resource-limited setting
Main Article Content
Abstract
Objective: Non- Hodgkin’s lymphoma is a relatively uncommon cancer and outcome data in Indian setting is scarce. This study aimed to evaluate the accessibility to rituximab and its impact on treatment outcomes in major non-Hodgkin's lymphoma (NHL) subtypes at a tertiary care cancer hospital in South India.
Methods: This was a single-centre, hospital-based retrospective study of all newly diagnosed NHL patients between April 2015 and March 2020, at Kidwai Memorial Institute of Oncology, Bengaluru, Karnataka. Case files of the patients were retrieved, relevant data was collected and analysed.
Results: In total, 929 patients were diagnosed with NHL [diffuse large B-cell lymphoma =478(51.4%), follicular lymphoma =82(8.8%), mantle cell lymphoma=65(6.9%), peripheral T-cell lymphoma=50(5.4%), and high-grade B-cell lymphoma=49(5.2%) and rest others]. Diffuse large B cell lymphoma patients mostly presented with stage IV disease (n=162(33.5%)). More than one-third (188(39.3%)) of the patients had extra-nodal disease with gastrointestinal tract involvement being the most common. The median progression free survival and overall survival of diffuse large B cell lymphoma patients were 15.2 and 23 months respectively. Only 37% of these patients had access to rituximab, and those who received rituximab-based chemotherapy demonstrated significantly better overall survival (HR=0.64, p=0.001). Follicular lymphoma patients also presented primarily with stage IV (n=40(49%)) disease, with 31(37.8%) and 58(70%) patients showing bone marrow involvement and extra-nodal involvement respectively. The median progression free survival and overall survival for these patients were not reached, however, the 2-year median progression free survival was 75%. Only 58% of the follicular lymphoma patients had access to rituximab. Response rates were higher with rituximab-based therapy, with complete response rates of 62% with rituximab vs 49% without rituximab. The progression free survival of patients who received rituximab was 61 months vs 41 months for those who did not (p=0.012).
Conclusion: There is significant gap in treatment outcomes of NHL patients between richer and poorer countries. There is an urgent need for framing of policies and public health interventions to improve access to newer therapies in resource constrained countries to further enhance cancer treatment outcomes.
Article Details
The Medical Research Archives grants authors the right to publish and reproduce the unrevised contribution in whole or in part at any time and in any form for any scholarly non-commercial purpose with the condition that all publications of the contribution include a full citation to the journal as published by the Medical Research Archives.
References
2. Bray F, Laversanne M, Sung H, et al. Global Cancer Statistics 2022: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. Ca (Print). 2024;74(3). doi: https://doi.org/10.3322/caac.21834
3. Morton LM, Zheng T, Holford TR, et al. Alcohol consumption and risk of non-Hodgkin lymphoma: a pooled analysis. Lancet Oncology. 2005;6(7):469-476. doi:https://doi.org/10.1016/s1470-2045(05)70214-x
4. Boffetta P. I. Epidemiology of adult non-Hodgkin lymphoma. Annals of Oncology. 2011;22: iv27-iv31. doi:https://doi.org/10.1093/annonc/mdr167
5. Chiu BCH ., Weisenburger DD. An Update of the Epidemiology of Non-Hodgkin’s Lymphoma. Clinical Lymphoma. 2003;4(3):161-168. doi: https://doi.org/10.3816/clm.2003.n.025
6. What is Non-Hodgkin lymphoma?: Types of non-hodgkin lymphoma. Types of Non-Hodgkin Lymphoma | American Cancer Society. Accessed August 11, 2024. https://www.cancer.org/cancer/types/non-hodgkin-lymphoma/about/what-is-non-hodgkin-lymphoma.html .
7. Bhutani M, Vora A, Kumar L, Kochupillai V. Lympho-hemopoietic Malignancies in India. Medical Oncology. 2002;19(3):141-152. doi: https://doi.org/10.1385/mo:19:3:141
8. Patel GR. Clinical spectrum and subtype distribution of Non Hodgkin’s Lymphoma based on the World Health Organization classification of tumors of lymphoid tissues (2017): an analysis from a tertiary care center in Western India. World cancer research journal. Published online 2023. doi:10.32113/wcrj_20235_2551
9. Sarma S, Mehta J. Spectrum of lymphomas in India. International journal of molecular and immuno oncology. 2024;9:16-24. doi: https://doi.org/10.25259/ijmio_18_2023
10. Plosker GL, Figgitt DP. Rituximab. Drugs. 2003;63(8):803-843. doi: https://doi.org/10.2165/00003495-200363080-00005
11. Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127(20):2375-2390. doi: https://doi.org/10.1182/blood-2016-01-643569
12. Olweny CL. Cotswolds modification of the Ann Arbor staging system for Hodgkin's disease. J Clin Oncol. 1990;8(9):1598.
13. A Predictive Model for Aggressive Non-Hodgkin’s Lymphoma. New England Journal of Medicine. 1993;329(14):987-994. doi: https://doi.org/10.1056/nejm199309303291402
14. Solal-Celigny P. Follicular Lymphoma International Prognostic Index. Blood. 2004;104(5):1258-1265. doi: https://doi.org/10.1182/blood-2003-12-4434
15. Cheson BD, Fisher RI, Barrington SF, et al. Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification. Journal of Clinical Oncology. 2014;32(27):3059-3067. doi: https://doi.org/10.1200/jco.2013.54.8800
16. Morton LM. Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. Blood. 2006;107(1):265-276. doi: https://doi.org/10.1182/blood-2005-06-2508
17. Ruchlemer R, Polliack A. Geography, ethnicity and “roots” in chronic lymphocytic leukemia. Leukemia & Lymphoma. 2012;54(6):1142-1150. doi: https://doi.org/10.3109/10428194.2012.740670
18. Yang QP, Zhang WY, Yu JB, et al. Subtype distribution of lymphomas in Southwest China: Analysis of 6,382 cases using WHO classification in a single institution. Diagnostic Pathology. 2011;6 (1). doi: https://doi.org/10.1186/1746-1596-6-77
19. Xu J, Yoshihiko Hoshida, Yang W, et al. Life‐style and environmental factors in the development of nasal NK/T‐cell lymphoma: A case–control study in East Asia. International journal of cancer. 2006;120(2):406-410. doi: https://doi.org/10.1002/ijc.22313
20. Naresh KN, Srinivas V, Soman CS. Distribution of various subtypes of non-Hodgkin’s lymphoma in India: A study of 2773 lymphomas using R.E.A.L. and who classifications. Annals of Oncology. 2000;11. doi:10.1093/annonc/11.suppl_1.s63
21. Mondal S, Mandal P, Roy S, Chattopadhyay S, Roy S, Biswas P. Malignant lymphoma in Eastern India: A retrospective analysis of 455 cases according to World Health Organisation classification. Journal of Cancer Research and Therapeutics. 2014;10(2):354. doi: https://doi.org/10.4103/0973-1482.136639
22. Pfreundschuh M, Kuhnt E, Trümper L, et al. CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group. The Lancet Oncology. 2011;12(11):1013-1022. doi: https://doi.org/10.1016/s1470-2045(11)70235-2
23. Habermann TM, Weller EA, Morrison VA, et al. Rituximab-CHOP Versus CHOP Alone or With Maintenance Rituximab in Older Patients With Diffuse Large B-Cell Lymphoma. Journal of Clinical Oncology. 2006;24(19):3121-3127. doi: https://doi.org/10.1200/jco.2005.05.1003
24. A Predictive Model for Aggressive Non-Hodgkin’s Lymphoma. New England Journal of Medicine. 1993;329(14):987-994. doi: https://doi.org/10.1056/nejm199309303291402
25. Sathyanarayanan V, Flowers CR, Iyer SP. Comparison of Access to Novel Drugs for Lymphoma and Chronic Lymphocytic Leukemia Between India and the United States. JCO Global Oncology. 2020;(6):1124-1133. doi: https://doi.org/10.1200/go.20.00012
26. Prakash G, Sharma A, Raina V, Kumar L, Mehar Chand Sharma, Bidhu Kalyan Mohanti. B cell non-Hodgkin’s lymphoma: experience from a tertiary care cancer center. Annals of Hematology. 2012;91(10):1603-1611. doi: https://doi.org/10.1007/s00277-012-1491-5
27. Ganesan P, Sagar TG, Kannan K, et al. Long-term outcome of diffuse large B-cell lymphoma: Impact of biosimilar rituximab and radiation. Indian J Cancer. 2017;54(2):430-435. doi:10.4103/ijc.IJC_241_17
28. Kumar L, Kn N, Gujral S, Kulkarni P, Stockler MR, Nair R. Editorial: Real World Outcomes of Lymphoma From India. Front Oncol. 2022;12:9223 70. Published 2022 Jul 19. doi:10.3389/fonc.2022. 922370
29. Ammar Almaaytah. Budget Impact Analysis of Switching to Rituximab’s Biosimilar in Rheumatology and Cancer in 13 Countries Within the Middle East and North Africa. ClinicoEconomics and outcomes research. 2020;Volume 12:527-534. doi: https://doi.org/10.2147/ceor.s265041
30. Seer incidence data - Seer Data & Software. SEER. Accessed August 11, 2024. https://seer.cancer.gov/data/ .
31. Tilly H, Morschhauser F, Sehn LH, et al. Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma. New England Journal of Medicine. 2022;386(4):351-363. doi: https://doi.org/10.1056/nejmoa2115304
32. Adhikarimayum Ambika Devi, Takhenchangbam Dhaneshor Sharma, Yengkhom Indibor Singh, Sonia H. Clinicopathological profile of patients with non-hodgkin’s lymphoma at a regional cancer center in Northeast India. Journal of the scientific society. 2017;44(3):140-140. doi: https://doi.org/10.4103/jss.jss_42_17
33. Mahanta D, Sharma J, Sarma A, Ahmed S, Kakoti L, Kataki A. Pattern of non-hodgkin lymphoma in a tertiary care center in Northeast India using morphology and immunohistochemistry. Indian Journal of Medical and Paediatric Oncology. 2019;40(4):595. doi: https://doi.org/10.4103/ijmpo.ijmpo_129_18
34. Arora N, Manipadam MT, Nair S. Frequency and distribution of lymphoma types in a tertiary care hospital in South India: analysis of 5115 cases using the World Health Organization 2008 classification and comparison with world literature. Leukemia & Lymphoma. 2012;54(5):1004-1011. doi:https://doi.org/10.3109/10428194.2012.729056
35. Gogia A, Das CK, Kumar L, Sharma A, Sharma MC, Mallick S. Profile of non-Hodgkin lymphoma: An Indian perspective. South Asian Journal of Cancer. 2018;07(03):162-170. doi: https://doi.org/10.4103/sajc.sajc_60_18
36. Ajay Gogia, Nair S, Sharma A, et al. Non-Hodgkin lymphoma: The Indian scene. Journal of clinical oncology. 2020;38(15_suppl):e20063-e20063. doi:https://doi.org/10.1200/jco.2020.38.15_suppl.e20063 .
37. Nair S, Gogia A, Arora S, et al. Clinicopathologic features and outcomes of diffuse large B-cell lymphoma with extranodal involvement: A retrospective analysis. Cancer research, statistics, and treatment/Cancer research, statistics and treatment. 2022;5(1):67-67. doi: https://doi.org/10.4103/crst.crst_204_21
38. Pavlovsky M, Cubero D, Agreda-Vásquez GP, et al. Clinical Outcomes of Patients With B-Cell Non-Hodgkin Lymphoma in Real-World Settings: Findings From the Hemato-Oncology Latin America Observational Registry Study. JCO Global Oncology. 2022;(8). doi: https://doi.org/10.1200/go.21.00265
39. Gogia A, Raina V, Kumar L, Sharma A, Sharma MC, Mallick SR. Follicular lymphoma: an Institutional Analysis. Asian Pacific Journal of Cancer Prevention: APJCP. 2017;18(3):681-685. doi:https://doi.org/10.22034/APJCP.2017.18.3.681